Lloyd Armbrust launches RonanRX to personalize GLP-1 dosing with AI
The two-time YC founder is pairing physician-set doses with compounded tirzepatide as regulators tighten scrutiny and telehealth rivals crowd the category.
By RuntimeWire Staff · Published
Primary source: RonanRX
Why it matters
RonanRX is testing whether software-guided, physician-controlled dosing can distinguish a compounded GLP-1 service as FDA scrutiny rises and larger telehealth providers expand access to approved drugs.
Lloyd Armbrust and Emily Colman launched RonanRX, an AI-assisted care platform that uses patient data to help physicians tailor compounded GLP-1 doses rather than moving everyone through the same escalation schedule.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.